BTIG issued brief commentary on Allergan (NYSE: AGN) following the U.S. Treasury's tax inversion actions on Monday night.Analyst Timothy Chiang ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger TerminationApril 6, 2016 10:42 AM Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO SearchApril 6, 2016 10:10 AM Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations April 6, 2016 7:13 AM Allergen's (AGN) Stand-Alone Price Target is $282 at Deutsche BankApril 5, 2016 3:45 PM UPDATE: Valeant (VRX) Said Willing to Offer Better Terms to Lenders in Order to Obtain Default WaiverApril 5, 2016 2:49 PM Conclusion of Valeant's (VRX) Ad Hoc Committee Review is Positive Development - Moody'sApril 5, 2016 2:18 PM Exclusive: Pfizer leaning toward abandoning deal with Allergan - sourceApril 5, 2016 1:55 PM Valeant (VRX) Could Be on the Verge of a Significant Inflection Point - BMO CapitalApril 5, 2016 10:09 AM Pfizer (PFE), Allergan (AGN) deal appears likely to be dead - CNBC's FaberApril 5, 2016 10:05 AM